UNICLE BIOMEDICAL DATA SCIENCE: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
UNICLE BIOMEDICAL DATA SCIENCE
Largest movements
- Cash -€125,969
down €125,969 (-51.8%), from €243,331 to €117,362
mainly Net result for the year (-€66,856) and Trade debts (-€25,040)
- Receivables within one year +€24,885
up €24,885 (+70.2%), from €35,440 to €60,325
of which Trade receivables: +€27,836
- Deferred charges and accrued income +€5,080
new in 2025: €5,080
- Tangible fixed assets -€2,993
down €2,993 (-64.8%), from €4,620 to €1,627
of which Furniture and vehicles: -€2,889
- Profit (loss) carried forward -€66,856
down €66,856 (-28.5%), from €234,557 to €167,701
- Trade debts -€25,040
down €25,040 (-74.4%), from €33,675 to €8,634
- Tax, wage and social debts -€6,261
no longer reported in 2025 (was €6,261)
- Gross operating margin -€243,046
down €243,046, from €183,753 to -€59,294
- Staff costs -€49,098
down €49,098 (-92.0%), from €53,390 to €4,292
- Other operating charges +€21,282
up €21,282 (+5,494%), from €387 to €21,670
- Write-downs -€21,270
new in 2025: -€21,270
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €287,826 | €188,381 | -€99,445 | -34.6% |
| Fixed assets | 21/28 | €9,055 | €5,614 | -€3,442 | -38.0% |
| Intangible fixed assets | 21 | €3,435 | €2,987 | -€448 | -13.1% |
| Tangible fixed assets | 22/27 | €4,620 | €1,627 | -€2,993 | -64.8% |
| Plant, machinery and equipment | 23 | €104 | - | -€104 | |
| Furniture and vehicles | 24 | €4,516 | €1,627 | -€2,889 | -64.0% |
| Financial fixed assets | 28 | €1,000 | €1,000 | = | 0.0% |
| Current assets | 29/58 | €278,770 | €182,767 | -€96,003 | -34.4% |
| Amounts receivable within one year | 40/41 | €35,440 | €60,325 | +€24,885 | +70.2% |
| Trade receivables | 40 | €26,992 | €54,828 | +€27,836 | +103% |
| Other amounts receivable | 41 | €8,448 | €5,497 | -€2,951 | -34.9% |
| Cash at bank and in hand | 54/58 | €243,331 | €117,362 | -€125,969 | -51.8% |
| Deferred charges and accrued income | 490/1 | - | €5,080 | +€5,080 | |
| Total equity and liabilities | 10/49 | €287,826 | €188,381 | -€99,445 | -34.6% |
| Equity | 10/15 | €239,557 | €172,701 | -€66,856 | -27.9% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €234,557 | €167,701 | -€66,856 | -28.5% |
| Amounts payable | 17/49 | €48,269 | €15,680 | -€32,589 | -67.5% |
| Amounts payable within one year | 42/48 | €39,936 | €8,930 | -€31,006 | -77.6% |
| Trade debts | 44 | €33,675 | €8,634 | -€25,040 | -74.4% |
| Suppliers | 440/4 | €33,675 | €8,634 | -€25,040 | -74.4% |
| Taxes, remuneration and social security | 45 | €6,261 | - | -€6,261 | |
| Remuneration and social security | 454/9 | €6,261 | - | -€6,261 | |
| Other amounts payable | 47/48 | - | €295 | +€295 | |
| Accrued charges and deferred income | 492/3 | €8,333 | €6,750 | -€1,583 | -19.0% |
| Remuneration, social security and pensions | 62 | €53,390 | €4,292 | -€49,098 | -92.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €3,751 | €3,442 | -€309 | -8.2% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | - | -€21,270 | -€21,270 | |
| Other operating charges | 640/8 | €387 | €21,670 | +€21,282 | +5,494% |
| Gross operating margin | 9900 | €183,753 | -€59,294 | -€243,046 | |
| Operating profit (loss) | 9901 | €126,224 | -€67,428 | -€193,652 | |
| Financial income | 75/76B | €1,002 | €894 | -€108 | -10.8% |
| Recurring financial income | 75 | €1,002 | €894 | -€108 | -10.8% |
| Financial charges | 65/66B | €357 | €322 | -€35 | -9.7% |
| Recurring financial charges | 65 | €357 | €322 | -€35 | -9.7% |
| Profit (loss) for the period before taxes | 9903 | €126,869 | -€66,856 | -€193,725 | |
| Profit (loss) for the period | 9904 | €126,869 | -€66,856 | -€193,725 | |
| Profit (loss) for the period to be appropriated | 9905 | €126,869 | -€66,856 | -€193,725 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 31 October 2026 via checked.be.